Targeting mTOR signaling for cancer therapy.

Autophagy in cell death: an innocent convict? J Clin Invest (2005) 10.70

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00

Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev (2005) 2.56

The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38

Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem (2007) 1.81

Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem (2010) 1.44

Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res (2009) 1.39

S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood (2011) 1.39

The complexes of mammalian target of rapamycin. Curr Protein Pept Sci (2010) 1.33

Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death. Free Radic Biol Med (2010) 1.28

Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin. Mol Biol Cell (2007) 1.28

Updates of mTOR inhibitors. Anticancer Agents Med Chem (2010) 1.27

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs (2004) 1.23

Protein kinases and phosphatases in the control of cell fate. Enzyme Res (2011) 1.23

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19

mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr (2010) 1.13

Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer (2011) 1.10

mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem (2010) 1.09

Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol Cancer (2010) 1.08

A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene (2006) 1.08

Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol (2009) 1.07

Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med (2012) 1.03

Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. Neuro Oncol (2011) 1.02

New concepts in phospholipase D signaling in inflammation and cancer. ScientificWorldJournal (2010) 1.01

Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res (2005) 1.00

Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res (2013) 1.00

Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene (2009) 0.97

Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope (2010) 0.96

CaMKII is involved in cadmium activation of MAPK and mTOR pathways leading to neuronal cell death. J Neurochem (2011) 0.95

Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. J Biol Chem (2010) 0.94

Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol (2011) 0.94

Rapamycin preserves gut homeostasis during Drosophila aging. Oncotarget (2015) 0.93

A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget (2014) 0.92

The physiology and pathophysiology of rapamycin resistance: implications for cancer. Cell Cycle (2011) 0.91

Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation. Mol Cell Biol (2013) 0.91

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res (2014) 0.90

Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy. Int J Mol Sci (2012) 0.90

Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest (2004) 0.90

Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget (2015) 0.90

Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol (2005) 0.89

Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89

Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. Hum Mol Genet (2013) 0.89

Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells. Oncotarget (2014) 0.88

Modeling resistance to pathway-targeted therapy in ovarian cancer. Cell Cycle (2005) 0.88

YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Sci Rep (2014) 0.88

Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling. PLoS One (2015) 0.87

LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated. Genes Dis (2014) 0.87

High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch (2010) 0.87

Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics (2013) 0.87

Downregulation of protein kinase CK2 induces autophagic cell death through modulation of the mTOR and MAPK signaling pathways in human glioblastoma cells. Int J Oncol (2012) 0.85

Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. PLoS One (2013) 0.85

New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review). Oncol Rep (2013) 0.84

MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. J Transl Med (2013) 0.83

The death effector domain-containing DEDD supports S6K1 activity via preventing Cdk1-dependent inhibitory phosphorylation. J Biol Chem (2008) 0.83

Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines. Cancer Sci (2014) 0.83

Modulatory effect of curcumin on survival of irradiated human intestinal microvascular endothelial cells: role of Akt/mTOR and NF-{kappa}B. Am J Physiol Gastrointest Liver Physiol (2010) 0.83

Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol (2015) 0.81

YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models. Br J Pharmacol (2013) 0.80

eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling. Oncotarget (2015) 0.78

The death effector domain-containing DEDD forms a complex with Akt and Hsp90, and supports their stability. Biochem Biophys Res Commun (2009) 0.78

Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Biochem Pharmacol (2016) 0.78

HRP-3 protects the hepatoma cells from glucose deprivation-induced apoptosis. Int J Clin Exp Pathol (2015) 0.78

Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors. Cancer Med (2014) 0.77

The relationship between mTOR signalling pathway and recombinant antibody productivity in CHO cell lines. BMC Biotechnol (2014) 0.76

Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways. Drug Des Devel Ther (2016) 0.76

Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach. Genetics (2016) 0.75

Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells. Drug Des Devel Ther (2016) 0.75

Tumor cells undergoing direct lineage conversion to neurons: unnatural but useful? Neural Regen Res (2015) 0.75

Cluster Analysis of Tumor Suppressor Genes in Canine Leukocytes Identifies Activation State. Bioinform Biol Insights (2016) 0.75

Differential Role of Rapamycin and Torin/KU63794 in Inflammatory Response of 264.7 RAW Macrophages Stimulated by CA-MRSA. Int J Inflam (2014) 0.75

N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells. J Exp Clin Cancer Res (2016) 0.75

B Cell Receptor Activation Predominantly Regulates AKT-mTORC1/2 Substrates Functionally Related to RNA Processing. PLoS One (2016) 0.75

Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions. Bioinformation (2015) 0.75

Inhibition of Mammalian Target of Rapamycin (mTOR) Signaling in the Insular Cortex Alleviates Neuropathic Pain after Peripheral Nerve Injury. Front Mol Neurosci (2017) 0.75

An eIF4E-interacting peptide induces cell death in cancer cell lines. Cell Death Dis (2014) 0.75

Reprogramming A375 cells to induced‑resembled neuronal cells by structured overexpression of specific transcription genes. Mol Med Rep (2016) 0.75

Decreased Phosphorylated Protein Kinase B (Akt) in Individuals with Autism Associated with High Epidermal Growth Factor Receptor (EGFR) and Low Gamma-Aminobutyric Acid (GABA). Biomark Insights (2015) 0.75

β-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling. Oncol Lett (2015) 0.75

IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells. Cytokine (2016) 0.75

The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99

Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2.54

Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31

mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25

Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 2.25

Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol (2006) 2.21

Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12

Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91

IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88

Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell (2003) 1.84

Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res (2005) 1.83

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71

Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66

Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res (2003) 1.63

Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem (2002) 1.61

Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol (2007) 1.61

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res (2006) 1.58

Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs (2002) 1.52

Retracted FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol (2005) 1.51

Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav (2003) 1.48

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther (2011) 1.45

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res (2004) 1.41

Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem (2005) 1.41

Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol (2006) 1.38

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem (2002) 1.37

Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem (2004) 1.37

Antioxidant activity of methanol extracts obtained from Plantago species. J Agric Food Chem (2005) 1.32

Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther (2006) 1.32

Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat Med (2003) 1.30

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30

Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol (2009) 1.29

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther (2007) 1.28

In vitro cytotoxic activity of Thai medicinal plants used traditionally to treat cancer. J Ethnopharmacol (2004) 1.27

Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics (2002) 1.26

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res (2004) 1.26

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.26

Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res (2003) 1.26

Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Cancer Res (2003) 1.26

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.25

SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer (2008) 1.23

Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res (2006) 1.23

RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther (2013) 1.21

Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Cancer Res (2013) 1.20

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.20

Cardiovascular effects of ginger aqueous extract and its phenolic constituents are mediated through multiple pathways. Vascul Pharmacol (2005) 1.18

A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res (2003) 1.17

IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell (2006) 1.17

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer (2013) 1.16

Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J Biol Chem (2002) 1.16

Antibacterial, antioxidant and fibroblast growth stimulation of aqueous extracts of Ficus asperifolia Miq. and Gossypium arboreum L., wound-healing plants of Ghana. J Ethnopharmacol (2008) 1.15

Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.14

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther (2011) 1.13

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 1.13

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 1.13

Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol (2005) 1.12

Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity. Phytother Res (2007) 1.11

The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Mol Cell Biol (2009) 1.11

Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harb Perspect Med (2014) 1.10

Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets (2004) 1.10

Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo. Mol Cell Biol (2007) 1.09

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 1.08

In vitro inhibitory activities of plants used in Lebanon traditional medicine against angiotensin converting enzyme (ACE) and digestive enzymes related to diabetes. J Ethnopharmacol (2008) 1.07

Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs (2007) 1.06

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.05

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.05

O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther (2002) 1.04

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol (2006) 1.03

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2012) 1.03

Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Stat Med (2005) 1.03

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03

miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci Signal (2013) 1.02

Wilms tumor suppressor 1 (WT1) and early growth response 1 (EGR1) are regulators of STIM1 expression. J Biol Chem (2010) 1.02

Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol (2004) 1.02

Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res (2002) 1.01

Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta Med (2004) 1.00

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.00

Wound healing activity of acylated iridoid glycosides from Scrophularia nodosa. Phytother Res (2002) 1.00

Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One (2012) 0.99

Anti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small molecule. PLoS One (2012) 0.99

mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. J Biol Chem (2007) 0.99

Virtual docking approaches to protein kinase B inhibition. J Med Chem (2005) 0.98

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 0.98

Muscarinic, Ca(++) antagonist and specific butyrylcholinesterase inhibitory activity of dried ginger extract might explain its use in dementia. J Pharm Pharmacol (2008) 0.98

5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance. J Med Chem (2005) 0.97

Flavone C-glycosides from Viola yedoensis MAKINO. Chem Pharm Bull (Tokyo) (2003) 0.97

p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage. J Biol Chem (2013) 0.96

Protective effect of Pimpinella anisoides ethanolic extract and its constituents on oxidative damage and its inhibition of nitric oxide in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Med Food (2010) 0.96

In vitro evaluation of effects of two Ghanaian plants relevant to wound healing. Phytother Res (2006) 0.96

Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival. Cancer Biol Ther (2008) 0.95

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 0.95

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 0.95

Activity against Mycobacterium smegmatis and M. tuberculosis by extract of South African medicinal plants. Phytother Res (2008) 0.95

Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 0.95